Glenmark reports net profit at Rs 234 crore in Q2
New Delhi: Drug firm Glenmark Pharmaceuticals on Friday reported a consolidated net profit of Rs 233.99 crore for the second quarter ended September 30.
The company had posted a net profit of Rs 255.54 crore for the same period previous fiscal, Glenmark said in a BSE filing.
Its consolidated revenue stood at Rs 2,952.47 crore for the quarter under consideration. It was Rs 2,815.04 crore for the same period a year ago, it added.
"The net profit is not comparable on account of forex gain recorded in the previous corresponding quarter of the financial year 19-20," Glenmark said in the regulatory filing.
Commenting on the results, Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said: "Our relentless focus on costs and new product introductions during these challenging times have helped increase revenue and operating profit in the second quarter of this financial year".
India and active pharmaceutical ingredient (API) business performed well along with the Europe and ROW region, he added.
Read also: Glenmark gets USFDA nod to generic version of Rapamune
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd